Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry.Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry (2012-2014; n = 12), and earlier HIT trials (n = 4) were selected for analysis.Age-adjusted incidence rate was 1.35 per 1 million children (aged 1-4 years) in the years 2012-2014. Median age at diagnosis for 35 patients was 2.9 years. Metastases at diagnosis were detected in 9 patients. One patient died due to postoperative complications. For 30 patients with non-brainstem tumor location, 5-year progression-free survival (PFS) and overall survival (OS) were 35% and 47% after treatment with CARBO/ETO + HDCT (n = 17), compared to 0% and 8% with other treatments (n = 13, P[OS] = .011). All 4 patients with brainstem tumor died within 10 months after diagnosis. By multivariable analysis, supratentorial location: (HR [PFS]: 0.07 [95%CI: 0.01-0.38], P = .003), localized disease (M0): (HR [OS] M0, no residual tumor: 0.30 [95%CI: 0.009-1.09], P = .068; M0, residual tumor: 0.18 [95%CI: 0.04-0.76], P = .020), and CARBO/ETO + HDCT treatment (HR [OS]: 0.16 [95%CI: 0.05-054], P = .003) were identified as independent prognostic factors. Of 9 survivors, 6 were treated with radiotherapy (craniospinal 4; local 2).Our data indicate improved survival with intensified chemotherapy (CARBO/ETO + HDCT). However, despite intensive treatment, the outcome was poor. Thus, innovative therapies need to be evaluated urgently in an upfront setting.
geriatrics; malnutrition; older adults; preventive care; smart home
Malnutrition is a well-known risk factor for deteriorated physical function, disability and loss in independence in older adults. An unintended loss in body weight of more than 5% in 3 months is one indicator for malnutrition. In this study we examined the relationship between meal preparation time, hand grip strength, and body weight in order to map impending nutritional problems using ambient sensors. Data were collected in the domestic environments of 20 (pre-) frail older adults aged 85.75 y (Standard Deviation: 5.19 y) over 10-months of observation. Collecting included physical function and nutritional status of the participants and meal preparation time by a combination of motion and power sensor events. Analysis was done by rank correlation of hand grip strength, body weight, and meal preparation time. Ten participants aged 85.1 years (Standard Deviation: 4.6 y) were included. The results show a significant correlation (≥0.99) of the meal preparation time with the hand grip strength. This result validated the meal preparation time as a suitable measure for analysing the correlation between meal preparation time and body weight, and a significant correlation (≥0.99) found. Hence the meal preparation time could be used as an indicator for malnutrition. However, causalities have to be conducted by further clinical studies.
International journal of ubicomp [Erscheinungsort nicht ermittelbar] : Academy & Industry Research Collaboration Center (AIRCC), 2010 12(2021), 1/2, Seite 1-15 Online-Ressource
Tentori, Monica Adjunct Proceedings of the 2020 ACM International Joint Conference on Pervasive and Ubiquitous Computing and Proceedings of the 2020 ACM International Symposium on Wearable Computers New York,NY,United States : Association for Computing Machinery, 2020 (2020), Seite 305-310 1 online resource (732 pages)
International Conference on Signal, Image Processing and Pattern Recognition (9. : 2020 : Online) 9th International Conference on Signal, Image Processing and Pattern Recognition (SPPR 2020), December 19-20, 2020, Sydney, Australia [Chennai, Tamil Nadu, India] : AIRCC Publishing Corporation, 2020 (2020), Seite 123-135 1 Online-Ressource (207 Seiten)
Tentori, Monica Adjunct Proceedings of the 2020 ACM International Joint Conference on Pervasive and Ubiquitous Computing and Proceedings of the 2020 ACM International Symposium on Wearable Computers New York,NY,United States : Association for Computing Machinery, 2020 (2020), Seite 408-413 1 online resource (732 pages)
International journal of computer vision & signal processing [Dhaka : Center for Natural Science & Engineering Research (CNSER), 2012 10(2020), 1, Seite 16-26 Online-Ressource
von Martin Mynarek ; Katja von Hoff ; Torsten Pietsch ; Holger Ottensmeier ; Monika Warmuth-Metz ; Brigitte Bison ; Stefan Pfister ; Andrey Korshunov ; Tanvi Sharma ; Natalie Jäger ; Marina Ryzhova ; Olga Zheludkova ; Andrey Golanov ; Elisabeth Jane Rushing ; Martin Hasselblatt ; Arend Wolfgang Koch ; Ulrich Schüller ; Andreas von Deimling ; Felix Sahm ; Martin Sill ; Markus Johannes Riemenschneider ; Hildegard Dohmen ; Camelia Maria Monoranu ; Clemens Sommer ; Ori Staszewski ; Christian Mawrin ; Jens Florian Schittenhelm ; Wolfgang Brück ; Katharina Johanna Filipski ; Christian Hartmann ; Matthias Meinhardt ; Klaus Pietschmann ; Christine Haberler ; Irene Slavc ; Nicolas U. Gerber ; Michael Grotzer ; Martin Benesch ; Paul-Gerhardt Schlegel ; Frank Deinlein ; André von Bueren ; Carsten Friedrich ; Björn-Ole Juhnke ; Denise Obrecht ; Gudrun Fleischhack ; Robert Kwiecien ; Andreas Faldum ; Rolf-Dieter Kortmann ; Marcel Kool ; Stefan Rutkowski
PURPOSEThe HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy.PATIENTS AND METHODSFrom 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided into iSHH-I and iSHH-II subtypes in the HIT-2000-BIS4 cohort and a validation cohort (n = 71) from the HIT group and Russia.RESULTSFive years after diagnosis, patients with desmoplastic medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN; n = 42) had 93% progression-free survival (5y-PFS), 100% overall survival (5y-OS), and 93% CSI-free (5y-CSI-free) survival. Patients with CMB/LCA (n = 45) had 37% 5y-PFS, 62% 5y-OS, and 39% 5y-CSI-free survival. Local radiotherapy did not improve survival in patients with CMB/LCA. All DMB/MBEN assessed by DNA methylation profiling belonged to the SHH-INF subgroup. Group 3 patients (5y-PFS, 36%; n = 14) relapsed more frequently than the SHH-INF group (5y-PFS, 93%; n = 28) or group 4 patients (5y-PFS, 83%; n = 6; P < .001). SHH-INF split into iSHH-I and iSHH-II subtypes in HIT-2000-BIS4 and the validation cohort, without prognostic impact (5y-PFS: iSHH-I, 73%, v iSHH-II, 83%; P = .25; n = 99). Intelligence quotient (IQ) was significantly lower in patients after CSI (mean IQ, 90 [no radiotherapy], v 74 [CSI]; P = .012).CONCLUSIONSystemic chemotherapy and intraventricular methotrexate led to favorable survival in both iSHH subtypes of SHH-activated DMB/MBEN with acceptable neurotoxicity. Survival in patients with non-wingless (WNT)/non-SHH disease with CMB/LCA was not improved by local radiotherapy. Patients with group 4 disease had more favorable survival rates than those with group 3 medulloblastoma.
Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 38(2020), 18, Seite 2028-2040 Online-Ressource
Seite 2 von 3
